Literature DB >> 2931939

Valproate: an updated review.

L Gram, K D Bentsen.   

Abstract

Valproate in all its aspects is comprehensively surveyed. Previous reviews covering various aspects such as mechanism of action, clinical pharmacology, clinical efficacy in epilepsy, febrile convulsions and other neurological disorders, side effects, teratogenicity and intoxications are discussed and updated (161 references).

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2931939     DOI： 10.1111/j.1600-0404.1985.tb00854.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  8 in total

1.  Inhibition of sterol but not fatty acid synthesis by valproate in developing rat brain in vivo.

Authors:  J P Bolaños; J M Medina; D H Williamson
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

2.  Transport of valproate and its effects on GABA uptake in astroglial primary culture.

Authors:  M Nilsson; E Hansson; L Rönnbäck
Journal:  Neurochem Res       Date:  1990-08       Impact factor: 3.996

3.  Sodium valproate and clonazepam for treatment-resistant panic disorder.

Authors:  A Ontiveros; R Fontaine
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

Review 4.  Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy.

Authors:  C L Faingold; R A Browning
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

5.  "In vivo" administration of valproate decreases t-[35S]butylbicyclophosphorothionate binding in the rat brain.

Authors:  A Concas; M P Mascia; E Sanna; G Santoro; M Serra; G Biggio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-03       Impact factor: 3.000

6.  Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers.

Authors:  R H Düsing
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 7.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

8.  Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Authors:  Carsten Saft; Thorsten Lauter; Peter H Kraus; Horst Przuntek; Juergen E Andrich
Journal:  BMC Neurol       Date:  2006-02-28       Impact factor: 2.474
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.